Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods

To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs). Ninety-six patients treated with DAAs, either alone (91) or in combination with...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2017-11, Vol.12 (11), p.e0187755
Main Authors: Loggi, Elisabetta, Galli, Silvia, Vitale, Giovanni, Di Donato, Roberto, Vukotic, Ranka, Grandini, Elena, Margotti, Marzia, Guarneri, Valeria, Furlini, Giuliano, Galli, Claudio, Re, Maria Carla, Andreone, Pietro
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antigens
Antiviral agents
Antiviral Agents - therapeutic use
Antiviral drugs
Assaying
Automation
Biology and life sciences
Complications and side effects
Conflicts of interest
Core protein
Correlation
Dosage and administration
Drug therapy
Fees & charges
Female
Genotype & phenotype
Hepatitis
Hepatitis Antibodies - blood
Hepatitis C
Hepatitis C - drug therapy
Hepatitis C - genetics
Hepatitis C virus
Humans
Infections
Infectious diseases
Interferon
Interferon-alpha - therapeutic use
Kinetics
Male
Medicine and health sciences
Middle Aged
Monitoring
Patients
Pharmaceuticals
Polyethylene glycol
Prognosis
Ribavirin - therapeutic use
Ribonucleic acid
RNA
Viral Load
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs). Ninety-six patients treated with DAAs, either alone (91) or in combination with PEG interferon (5), were tested for HCV-RNA and for HCV-Ag at baseline and at weeks 2, 4, 8 and 12 during treatment and 12 weeks after completion. The concordance and correlation between the viral parameters as well as the respective kinetics during and after treatment were evaluated. A sustained viral response (SVR) was achieved in 82 patients (91%), whereas 11 relapsed (R) and 1 showed a virological breakthrough while receiving treatment. HCV-RNA and HCV-Ag showed good concordance (kappa = 0.62) and correlation. No significant differences between SVR and R was observed in either assay at 2 and 4 weeks after the start of treatment. At 8 weeks, HCV-Ag showed higher accuracy than HCV-RNA (AUC: 0.74 vs. 0.55) and there was a significantly greater decrease from baseline in SVR than in R (4.01 vs. 3.36 log10; p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0187755